Pfizer: Parkinson Disease trials
The registry lists 15 Parkinson Disease studies with Pfizer as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 5Phase 2 4Phase 3 3Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT03185481Phase 2Results posted
- Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the DiseaseTerminatedNCT02847650Phase 2Results posted
- Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT02687542Phase 2Results posted
- PF-06669571 In Subjects With Idiopathic Parkinson's DiseaseCompletedNCT02565628Phase 1Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's DiseaseCompletedNCT02224664Phase 1Results posted
- Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)CompletedNCT01270711Results posted
- The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary EventsCompletedNCT01052948Results posted
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's DiseaseCompletedNCT02373072Phase 1
- A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed ConditionsCompletedNCT02184429Phase 1
- Efficacy, Safety And Tolerability Study In Subjects With Parkinson's DiseaseCompletedNCT02006290Phase 1
- Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.TerminatedNCT00174239Phase 4
- The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's DiseaseCompletedNCT00163085Phase 2
- Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's DiseaseCompletedNCT00058838Phase 3
- Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.CompletedNCT00036218Phase 3
- Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's DiseaseTerminatedNCT00036205Phase 3